Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management.
Dosimetry
Peptide receptor radionuclide therapy (PRRT)
SPECT/CT
[177Lu]-DOTA-TATE
Journal
EJNMMI physics
ISSN: 2197-7364
Titre abrégé: EJNMMI Phys
Pays: Germany
ID NLM: 101658952
Informations de publication
Date de publication:
23 Jan 2020
23 Jan 2020
Historique:
received:
15
09
2019
accepted:
16
01
2020
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
25
1
2020
Statut:
epublish
Résumé
After each cycle of [ The best agreement for the cumulative doses absorbed by the kidneys, bone marrow, liver, spleen, and tumors with the conventional protocol was obtained with the (t These preliminary results demonstrate that dosimetry calculations using two quantitative SPECT/CT studies acquired at 24 and 168 h after the first PRRT cycle are feasible and are in good agreement with the standard imaging protocol with no change in patient management decisions, while enabling improved patient comfort and reduced scanner and staff time.
Sections du résumé
BACKGROUND
BACKGROUND
After each cycle of [
RESULTS
RESULTS
The best agreement for the cumulative doses absorbed by the kidneys, bone marrow, liver, spleen, and tumors with the conventional protocol was obtained with the (t
CONCLUSION
CONCLUSIONS
These preliminary results demonstrate that dosimetry calculations using two quantitative SPECT/CT studies acquired at 24 and 168 h after the first PRRT cycle are feasible and are in good agreement with the standard imaging protocol with no change in patient management decisions, while enabling improved patient comfort and reduced scanner and staff time.
Identifiants
pubmed: 31975156
doi: 10.1186/s40658-020-0273-8
pii: 10.1186/s40658-020-0273-8
pmc: PMC6977807
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5Références
EJNMMI Phys. 2015 Dec;2(1):24
pubmed: 26501825
EJNMMI Phys. 2018 Dec 10;5(1):36
pubmed: 30535780
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1847-56
pubmed: 18427807
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):212-25
pubmed: 19727718
Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1138-46
pubmed: 19247653
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
EJNMMI Phys. 2018 Jun 19;5(1):10
pubmed: 29916115
BJR Case Rep. 2015 Aug 18;1(3):20150177
pubmed: 30363599
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):453-63
pubmed: 26419852
J Nucl Med. 2018 Mar;59(3):452-458
pubmed: 28775205
EJNMMI Phys. 2018 Jul 5;5(1):12
pubmed: 29974391
Acta Oncol. 2016 Sep - Oct;55(9-10):1069-1076
pubmed: 27219529
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):217-27
pubmed: 2032890
Nucl Med Commun. 2018 Mar;39(3):236-246
pubmed: 29315138
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1802-11
pubmed: 27160225
J Nucl Med. 2013 Jan;54(1):33-41
pubmed: 23223392
J Nucl Med. 2018 Jan;59(1):75-81
pubmed: 28588150
Appl Radiat Isot. 2001 Jul;55(1):89-96
pubmed: 11339536
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35
pubmed: 21892623
J Nucl Med. 2008 Nov;49(11):1884-99
pubmed: 18927342
EJNMMI Phys. 2018 Dec 20;5(1):33
pubmed: 30569328
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
Acta Oncol. 2012 Jan;51(1):86-96
pubmed: 21961497
Cancer Imaging. 2011 Jun 15;11:56-66
pubmed: 21684829
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12
pubmed: 22388631
J Nucl Med. 2016 Jan;57(1):151-62
pubmed: 26471692
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):152-154
pubmed: 29080096
J Nucl Med. 2007 Jan;48(1):134-42
pubmed: 17204710
J Nucl Med. 2009 Mar;50(3):477-84
pubmed: 19258258